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Genomewide association studies may offer the best promise for genetic mapping of complex traits. Such studies in
outbred populations require very densely spaced single-nucleotide polymorphisms. In recently founded population
isolates, however, extensive linkage disequilibrium (LD) may make these studies feasible with currently available
sets of short tandem repeat markers, spaced at intervals as large as a few centimorgans. We report the results of
a genomewide association study of severe bipolar disorder (BP-I), using patients from the isolated population of
the central valley of Costa Rica. We observed LD with BP-I on several chromosomes; the most striking results were
in proximal 8p, a region that has previously shown linkage to schizophrenia. This region could be important for
severe psychiatric disorders, rather than for a specific phenotype.
Introduction
The elucidation of the genetic basis of common, geneti-
cally complex diseases remains extremely difficult. Stan-
dard linkage analysis has so far proved unsatisfactory for
this task (Shork et al. 1998; Risch 2000). There is cur-
rently intense interest in searching for susceptibility genes
for such disorders, using association analysis (Risch and
Merikangas 1996), either through direct investigation of
variants in candidate genes or through linkage disequi-
librium (LD) mapping. LD mapping involves searching
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for association between a disease and alleles or haplotypes
at mapped marker loci. This association reflects sharing
of genome segments that surround a disease gene among
affected individuals who are descended from a common
ancestor. Such shared genome segments are, on average,
shorter in older populations than in younger populations,
reflecting the greater number of meioses separating af-
fected individuals from their common ancestors. In older
populations, including most outbred populations, LDwill
generally be detectable only over short distances (100
kb), and therefore genomewide LD mapping studies may
not be feasible before a very dense map of SNPs and
improved methods for high-throughput SNP genotyping
are available. In recently founded and genetically isolated
populations, however, LD may be detectable over much
longer genomic segments (i.e., spaced over intervals as
large as a few centimorgans) than in older and hetero-
geneous populations (Mohlke et al. 2001; Service et al.
2001; Varilo et al. 2001). Over these distances, it is pos-
sible to conduct genomewide genotyping, using currently
available sets of STR markers that have already been op-
timized for automated genotyping. This class of markers
is muchmore informative for detecting LD than are SNPs.
The higher mutation rate of STRs, compared with SNPs,
potentially inhibits the detection of LD; however, this is
a negligible factor over the relatively few meioses that
have occurred since the founding of young isolates. For
the reasons noted above, in recently founded population
566 Am. J. Hum. Genet. 71:565–574, 2002
isolates, genomewide LD mapping of complex traits may
be feasible with the use of STRmarkers spaced at intervals
as large as a few centimorgans.
LD mapping in recently founded isolates may be par-
ticularly powerful if it is feasible to construct haplotypes
among affected individuals. This approach has already
been used in such populations to map loci for several
Mendelian disorders (Houwen et al. 1994). For rare
Mendelian disorders, the expectation is that all affected
individuals from a population will share a common hap-
lotype in the region of the disease locus. In contrast, we
anticipate heterogeneity in disease etiology for a com-
plex trait, even in a population isolate. Therefore our
expectation is that not all affected individuals will share
ancestry and a common haplotype in the vicinity of a
trait locus; the goal of LD-based analysis is to identify
haplotypes shared more frequently by these individuals
than would be expected by chance.
Here, we report the results of a genomewide LD-map-
ping study of bipolar disorder (BP), a common syndrome
that consists of episodes of mania and depression and is
characterized by complex patterns of inheritance. Al-
though several genomewide linkage studies of BP have
been undertaken and have suggested several possible
chromosomal localizations, there is still no unequivocal
evidence for any single location for BP. In addition, these
studies have used a wide range of definitions of the af-
fected phenotype, and therefore their results are difficult
to compare with one another (Prathikanti andMcMahon
2001). We investigated a particularly severe and heritable
form of BP (BP-I) and further limited our studies to pro-
bands with BP-I who had at least two psychiatric hos-
pitalizations for this condition. We used a dense set of
STR markers to genotype 109 probands with BP-I and
their parents, a group drawn from a young population
isolate, that of the central valley of Costa Rica (CVCR).
The 2.6 million residents of the CVCR descend mainly
from a small group of Spanish and Amerindian founders
who lived in the 16th and 17th centuries; by the begin-
ning of the 18th century, the CVCR had a single popu-
lation that then grew rapidly, without subsequent im-
migration, for almost 200 years (Escamilla et al. 1996).
Its population history is similar to those of other isolates
that have been the focus of recent genetic-mapping efforts
(Peltonen et al. 2000; Chapman and Thompson 2001;
Shifman and Darvasi 2001).
The recent founding, isolation, and rapid expansion
of the CVCR population are reflected in the extensive
LD that has been observed in this population. A pre-
vious genomewide survey (Service et al. 2001) of back-
ground LD (BLD) (i.e., LD between markers indepen-
dent of a shared phenotype) in the CVCR population
showed that LD was significantly detectable in 310 of
1,012 adjacent marker pairs. These 310 marker pairs
were an average of ∼3 cM ( ) apart. For severalSDp 1.7
reasons, disease-related LD in this population is ex-
pected to display a more powerful signal than that of
BLD. First, if markers are spaced at an average density
of 3 cM (the average extent of BLD observed in the
CVCR population), a putative disease locus should be
no more than 1.5 cM distant from the nearest marker.
Using the markers available for the genome screen de-
scribed here, we were able to achieve an average density
of 3.5 cM (i.e., a disease locus should still be an average
of !2 cM from the nearest marker). In addition, al-
though the samples of control chromosomes used in the
investigation of BLD are essentially randomly chosen
with respect to LD, a sample of affected individuals in
a population isolate is, by definition, chosen to be en-
riched for LD in the region of disease-related variants.
Finally, disease-related LD may be assessed via haplo-
type-based tests that are substantially more powerful
than the two-point methods used to assess BLD. These
factors suggested that the ∼1,000 STR markers that we
used would be appropriate for an initial genomewide
screen for LD for BP-I in the CVCR. The results of this
screen are described here.
Subjects, Material, and Methods
Sample Collection
Individuals who experienced onset of BP-I at age50
years and had history of at least two psychiatric hos-
pitalizations were recruited, independently from one an-
other, from psychiatric hospitals and clinics (Escamilla
et al. 1996). Details of recruitment and diagnostic pro-
cedures are described elsewhere (Escamilla et al. 1996).
In brief, all subjects were interviewed by a bilingual
psychiatrist in Costa Rica, using the Diagnostic In-
terview for Genetic Studies (Nurnberger et al. 1994).
The interview results and abstracts of hospital records
were reviewed by two independent psychiatrists at the
University of California, San Francisco, to arrive at a
consensus best-estimate diagnosis. Fifty-eight probands
were women, and 51 were men. Both parents of 48
probands were available for genotyping, and the re-
maining 61 probands had one parent available, making
a total of 266 genotyped individuals (109 probands and
157 parents). Eighty-one probands had all eight great-
grandparents from the CVCR; 11 and 17 had seven and
six great-grandparents from the CVCR, respectively. The
majority of subjects in the current sample were not avail-
able in earlier LD analyses of chromosome 18 markers
in this population (Escamilla et al. 1999, 2001). The
first LD study on chromosome 18 (Escamilla et al. 1999)
used a sample of 113 people that included 48 affected
individuals. Of those 113, 56 are genotyped in the cur-
rent sample, including 26 affected individuals. In the
second LD analysis of chromosome 18, work was di-
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vided into two phases (Escamilla et al. 2001). The phase
I portion genotyped 162 people (69 affected individuals),
and the phase II portion (a follow-up of regions iden-
tified in phase I) genotyped 566 individuals (227 affected
individuals). In the present study, 103/162 people from
the phase I portion are genotoyped (41/69 affected in-
dividuals). Everyone genotyped in the present study was
also genotyped in the phase II portion of the LD analysis
of selected regions on chromosome 18 (Escamilla et al.
2001). Informed consent was obtained from all subjects
in the study.
Genotyping
The 1,186 fluorescently labeled microsatellitemarkers
were mainly from the Ge´ne´thon collection (Dib et al.
1996), and a single genetic map provided the location
of all the markers in relation to one other (Broman et
al. 1998). The genotype data from 150 markers were
discarded because of such problems as PCR failure and
difficulty in scoring or because of large-scale Mendelian
errors (null alleles). Of the remaining 1,036 markers, the
vast majority ( ) were selected from the ABInp 807
Prism Linkage Mapping Set HD-5 (Applied Biosystems).
The order and sex-averaged distance of the markerswere
based on the Marshfield map (Broman et al. 1998). Six-
teen intervals had a size of 7–10 cM; no intervals were
110 cM. PCR was performed using standard conditions
in PE 9700 PCR machines. PCR products were detected
using an ABI 377 sequencer and were analyzed by use
of GENESCAN and GENOTYPER software. All geno-
types were independently double scored. Data were
checked for Mendelian inheritance by use of the UN-
KNOWN program. For all markers, at least 100 pro-
bands of the total 109 had acceptable genotypes (average
108 probands). The average observed heterozygosity of
the markers was 77%.
Each marker was tested for Hardy-Weinberg equilib-
rium (HWE) by comparing the observed homozygosity
in the parental chromosomes with the values expected
on the basis of the allele frequencies that were calculated
from our sample.
Population Homogeneity Assessment
The method of Pritchard et al. (2000) uses multilocus
genotype data from unlinked markers to infer popula-
tion structure. We applied this method to the genotypes
of probands at 120 marker loci separated from one
another by at least 20 cM. In the application of this
Markov chain Monte Carlo method, we used 10,000
replications, for the burn-in period of the chain, and
100,000 replications, for parameter estimation. The
number of populations present in the sample (K) is
unknown, and we ran the analysis at , ,Kp 1 Kp 2
and . For each value of K, multiple chains wereKp 3
run and compared, to assess chain convergence and con-
sistency of estimates. From these results, the best esti-
mate of K was found by calculating the posterior prob-
abilities, as described by Pritchard et al. (2000)
Statistical Analysis of LD
LD was evaluated between markers and disease by
two statistical tests, a modified version (Escamilla et al.
1999) of the two-point method of Terwilliger (1995)
(LD-T) and a haplotype-based method, ancestral hap-
lotype reconstruction (AHR) (Service et al. 1999). We
used both tests for the following reason: AHR is ap-
parently more powerful than LD-T (Service et al. 1999);
however, LD-T, as a two-point test, is not sensitive to
BLD. The LD-T evaluates the likelihood that a particular
allele at a single locus is overrepresented on disease chro-
mosomes (transmitted), compared with nondisease chro-
mosomes (nontransmitted). This overrepresentation is
quantified by a single parameter, l. No correction for
multiple alleles is necessary with the LD-T, because the
likelihoods for individual alleles are weighted by allele
frequency and are combined into a single likelihood-
ratio test. The AHR method compares the observed dis-
tribution of haplotypes in affected individuals with the
distribution expected among individuals who bear a dis-
ease mutation inherited from a common ancestor (Ser-
vice et al. 1999). Nontransmitted chromosomes of par-
ents of probands were used as controls. The probability
model for AHR assumes a multinomial distribution of
the observed counts of haplotypes. The expected hap-
lotype probabilities are calculated by assuming a given
founder haplotype, the position of the disease locus (x),
the proportion of chromosomes in the sample of affected
individuals that is likely to have descended from this
founder haplotype (a), the separation time (in genera-
tions) from the common founding haplotype (g), and the
marker-allele frequencies. The likelihood of this putative
founder chromosome giving rise to the observed sample
of disease haplotypes can be easily calculated under the
assumptions of the multinomial distribution and the in-
dependence of chromosomes. These calculations are re-
peated for each of the putative founder chromosome
types, weighted by the probability of observing that hap-
lotype in the population, and are summed to create an
overall likelihood for the chromosomal segment. When
this approach is used, no correction for multiple hap-
lotypes at the same markers is needed. The likelihood is
maximized over x, g, and a and is compared with the
null likelihood. Under the null hypothesis, marker-allele
and haplotype frequencies (assuming a one-stepMarkov
process) are estimated, and a is set to zero.We calculated
the ratio of the log likelihoods (LR) under the alternative
hypothesis and under the null hypothesis. Under the null
hypothesis, 2*LR has half its weight concentrated on
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Figure 1 Distribution of the number of meiotic steps connect-
ing the 109 probands, calculated on the basis of available genealogical
information.
zero and the other half on a distribution that can be
approximated by max (X1,X2), where X1 and X2 are
independent x2 variables with 1 df (see Service et al.
1999). AHR was used in overlapping haplotype win-
dows, consisting of three markers each, on all auto-
somes; the model for recombination probabilities used
in haplotype-based tests that assume descent from a
common ancestor cannot be applied straightforwardly
to markers on sex chromosomes. The likelihood was
evaluated at five steps (estimates of x) between each
marker, at 15 estimates of g (ranging from 10 to 1,000),
and at 50 estimates of a (ranging from 0.02 to 1.0).
AHR was modified from the form presented by Service
et al. (1999) to allow for LD between markers under
the null hypothesis (McPeek and Strahs 1999). The cur-
rently observed LD is used as an estimate throughout
the population history.
These LD analyses were used to identify promising
regions for follow-up investigations, rather than to pro-
duce definitive localization, and we therefore applied a
low significance threshold. Previous simulations (Service
et al. 1999) had shown AHR to have a false-positive rate
that was in accordance with the rate predicted by a x2
distribution; however, those simulations were performed
under conditions of no BLD between markers in control
chromosomes. In the application of AHR to our data, we
were concerned that BLD could inflate the false-positive
rate of this test, and we therefore applied a higher thresh-
old for AHR ( ) than for LD-T ( ). The PP  .01 P  .05
values presented here are not corrected for multiple tests.
We view these results as a guide for further investigation,
rather than statistically significant associations.
By definition, regions with a high likelihood-ratio sta-
tistic have a higher likelihood under the model of descent
from a common disease-bearing ancestor than under the
null hypothesis of no disease locus present. Although the
observed data fit the alternative hypothesis better than
the null hypothesis, it is not necessarily true that the
data have a good fit to the alternative hypothesis. We
formulated a goodness-of-fit test by calculating the ex-
pected number of haplotypes of each type at the max-
imum-likelihood estimates of the parameters for both
case and control chromosomes. For the goodness-of-fit
test, we collapsed the haplotypes into six categories and
compared observed counts with expected counts in each.
The categories were formed by considering the possible
similarity of a three-marker haplotype to the most likely
founding haplotype: exactly like the founding haplotype,
different from the founding haplotype at flanking mark-
ers (four possibilities), and different from the founding
haplotype at each marker.
Results
Independent Samples from the Population Isolate
From available genealogical information, we calculated
the relatedness among the probands with BP-I. With 109
probands, there are a total of 5,886 possible pairwise
relationships ( ) to consider. We had ge-[109 # 108] 2
nealogical information to identify 900 of these 5,886
pairwise connections. These known pairwise connec-
tions were an average of 16 meiotic steps apart (see fig.
1). There were 47 probands for whom we have not iden-
tified relationships to other probands in the study. For the
majority (35) of these 47 probands, we had no genea-
logical information further than the great-grandparental
generation; therefore, the apparent lack of relatedness to
other probands is probably a result of incomplete infor-
mation. In fact, for 20 probands, we do not have gene-
alogical information on 1 or 2 of their great-grandparents.
The incomplete information connecting probands pre-
cludes the use of linkage tests in such a population sample,
because it is not possible simply to use this pedigree struc-
ture in a standard linkage program.
Statistical Analysis of LD
We genotyped the 109 probands with BP-I, each of
whom had at least one available parent, for 1,036 STR
markers spaced at an average distance from each other
of 3.5 cM. Analysis of these genotype data, by use of
the method of Pritchard et al. (2000), showed no evi-
dence for cryptic population substructure in this sample.
HWE was violated (with a significance level !.01), for
a total of 20 markers (data not shown). Reexamination
revealed only one marker that could be explained by the
presence of a potential null allele. This marker, D18S54,
was subsequently discarded from any further analysis.
For the other markers, HWE violation could not be ex-
plained other than by chance, and, after Bonferroni cor-
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Table 1
Markers for Which the LD-T P Value Was .05
Marker
Distance
from pter l P
Associated
Allele
D1S227 238.5 .250 .037 2
D2S2268 1.9 .450 .039 4
D2S2150 40.5 .303 .035 1
D2S303 88.2 .433 .009 1
D2S286 94.0 .355 .040 1
D4S413 158.0 .183 .044 5
D5S2049 160.9 .427 .039 2
D8S1825 15.4 .469 .022 3
D8S520 20.6 .252 .049 1
D9S1847 144.7 .352 .002 7
D10S602 4.3 .325 .027 4
D10S548 45.7 .399 .015 1
D10S208 60.6 .355 .015 6
D10S1773 134.2 .322 .050 3
D11S1320 141.9 .336 .021 4
D12S352 .0 .376 .018 5
D15S642 122.2 .339 .028 5
D17S787 75.0 .199 .046 6
D17S1862 97.6 .221 .044 4
D19S1150 39.0 .295 .020 1
D19S904 78.1 .282 .008 4
rection for multiple tests, only one marker (D6S434) was
significant at the .05 level.
The LD-T analysis showed 21 markers with evidence
of LD at a significance level of .05 (table 1), including
three markers (D2S303, D9S1847, and D19S904) show-
ing . The markers displaying association wereP ! .01
widely dispersed throughout the genome, except two
regions of ∼5 cM, each of which contained two markers
showing LD to BP-I (on chromosomes 2 and 8p).
The AHR analyses showed 14 regions with evidence
( ) for an overrepresented three-markerhaplotypeP  .01
(henceforth termed a “shared segment”) on the chromo-
somes transmitted to affected individuals (table 2). Three
of these regions are within 5 cM of markers showing LD
to BP-I by use of the LD-T (D8S503, D8S520, and
D17S788). In 4 of the 14 regions, consecutive shared seg-
ments overlapped with each other: on 2p, we observed
an overlap of five such shared segments; on 2q and 8p,
we observed an overlap of four segments; and, on 17p,
we observed overlap of three segments. We manually
examined haplotypes in these four regions. On 8p, the
overrepresentation of extended haplotypes among the
chromosomes transmitted to patients, compared with
nontransmitted chromosomes, is particularly apparent,
notably in the segment between D8S503 and D8S520.
In this segment, 139%of transmitted chromosomes have
either the 3-1 or 3-5 haplotype, compared with only
19% among nontransmitted chromosomes (table 3).
Compared with what is observed on 8p, the overrepre-
sentation on chromosomes of particular haplotypes
among affected individuals, compared with nontrans-
mitted chromosomes, is not as visually obvious in the
other three regions with evidence of overlapping hap-
lotype. Haplotype data from chromosome 17p are pre-
sented as examples (table 4).
The LD evidence in the AHR test derives from recon-
struction of a single most likely ancestral haplotype with
consequent estimation of (1) the proportion of chromo-
somes descended from this ancestral haplotype among the
affected individuals (parameter a) and (2) the number of
generations that have elapsed since this haplotype oc-
curred in a common ancestor of the affected individuals
(parameter g). For each region highlighted by the AHR
analysis, we determined whether the model of descent
from a single ancestral haplotype fits the observed dis-
tribution of haplotypes in the chromosomes from affected
individuals. For 7 of the 14 regions (D1S2841, D4S395,
D6S1575, D8S520, D9S257, D17S1828, and D17S788),
we observed reasonable goodness of fit in the chromo-
somes transmitted to affected individuals ( ). ForP 1 .10
the regions that had poor goodness of fit, the observed
LD is not fully explained by themodel of a single ancestral
susceptibility haplotype, and the parameter estimatesmay
be inaccurate. The results in these regions, however, are
still consistent with identical-by-descent sharing of hap-
lotypes among the affected individuals because of a shared
susceptibility gene in these regions.
We also evaluated goodness of fit of the nontrans-
mitted chromosomes to the distribution hypothesized by
AHR. This distribution is formed under the assumption
that LD is present between adjacent markers (modeled
as a one-step Markov process) but that linkage equi-
librium is present between nonadjacent markers; this
simplifying assumption may not hold for all genome
regions. Of the 14 regions shown in table 2, 5 (D4S395,
D8S520, D9S257, D17S1828, and D17S788) showed
reasonable goodness of fit to this model ( ). TheP 1 .10
lack of fit for other regions is probably a result of LD
between nonadjacent markers.
Discussion
The results described here demonstrate the application
of genomewide LD analysis for the mapping of suscep-
tibility loci for complex traits. We confirmed our initial
hypothesis that independently identified affected indi-
viduals in a recently founded genetic isolate would share
common ancestry. Genealogical information, although
incomplete, illustrates that the CVCR is a young and
inbred population. Indeed, such close relationship be-
tween independently ascertained probands is consistent
with the absence of demonstrable population substruc-
ture in this sample and with the extensive genomewide
LD observed in this population (Service et al. 2001), and
it confirms that the sample is suitable for genomewide
LD mapping.
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Table 2
Regions for Which the AHR Result Was Significant at a Level .01
Closest
Marker
Length of Three-
Marker Haplotype
(cM)
Estimate of Distance
from pter
of Disease Locus
Associated Three-
Marker Haplotype aa gb Pc
D1S2841 7.2 107.4 5 2 6 .08 27 .000987
D2S2241 4.4 157.5 9 5 4 .10 29 .002732
D2S156 4.9 164.5 2 4 1 .12 31 !.000001
D2S369 4.3 202.9 5 2 7 .06 17 .001217
D2S325 1.6 205.0 5 1 3 .08 17 .000390
D4S395 4.9 94.5 4 6 3 .08 10 .006305
D6S1575 2.6 61.6 6 2 2 .08 14 .003544
D8S503 5.2 17.1 3 3 1 .16 10 .000057
D8S520 5.8 20.6 1 10 3 .10 21 .000894
D8S1778 8.7 111.1 4 4 4 .06 13 .005137
D9S257 5.6 91.9 2 6 4 .04 10 .000325
D17S1529 6.0 3.9 3 8 2 .06 10 .000377
D17S1828 4.1 10.0 2 5 8 .06 40 .005015
D17S788 6.8 73.6 1 5 6 .12 10 .001897
a Maximum likelihood estimate of the proportion of disease chromosomes inherited from a common ancestor.
b Maximum likelihood estimate of the number of generations since that common ancestor.
c Based on x2 approximation.
Table 3
Distribution of Two-Marker Haplotypes
for D8S503-D8S520 Chromosomes Transmitted
and Nontransmitted from Parents to Probands
Haplotypea
Transmitted
(%)
Nontransmitted
(%)
1-1 3.43 4.72
2-5 4.57 5.51
3-1 22.86 12.60
3-2 2.86 3.15
3-4 4.00 5.51
3-5 16.57 7.87
3-6 4.00 4.72
5-4 .57 6.30
5-5 4.00 6.30
6-2 4.00 5.51
6-4 1.71 4.72
6-5 4.57 4.72
6-6 1.14 7.09
Other (n p 29) 25.71 21.26
a Haplotype counts of at least 5 for either trans-
mitted or nontransmitted categories are reported
here; counts !5 are grouped in the category “other.”
Our data indicate that, in a few genome regions, the
probands display haplotype sharing that is greater than
would be expected by chance. Because these haplotypes
are as long as several centimorgans, they are detectable
with the use of currently available sets of mapped STR
markers that have already been optimized for auto-
mated genotyping. We anticipate that the type of anal-
ysis that we report here could be used for initial map-
ping of loci for a wide range of complex traits, in any
of several populations with demographic histories sim-
ilar to that of the CVCR (e.g., in subisolates in Finland
in which LD has been observed for distances of several
centimorgans [Varilo et al. 2001]).
The genome screen for BP-I of this CVCR sample has
identified several candidate regions for further genetic
investigation, with the strongest evidence being for a
22-cM region on chromosome 8p. All of the overlap-
ping AHR analyses of this region provided evidence of
association with the disease (fig. 2), and four of the six
markers in this segment showed evidence of association
when analyzed by use of LD-T (fig. 2B, two markers
with ). In addition, the two LD tests (LD-T andP ! .05
AHR) identified the same alleles as being overrepre-
sented among the patients. The AHR analysis suggests
that the most likely localization of a BP-I gene is be-
tween D8S503 and D8S520. Direct observation of hap-
lotypes supports this conclusion, because the haplotypes
that were most common among the affected individuals
are observed more than twice as frequently in that group
as in the control individuals. It has been suggested that
the length of a region showing evidence of association
should be considered, as well as the magnitude of any
single peak within the region, with the idea that broader
peaks are more likely to contain a true locus (Terwilli-
ger et al. 1997). The mapping evidence over contig-
uous markers that cover several centimorgans makes
this region particularly attractive for follow-up. The seg-
ment in which we identified LD for BP-I overlaps with
those in which possible schizophrenia loci have been
identified through several independent linkage studies
(Blouin et al. 1998; Kaufmann et al. 1998; Brzustowicz
et al. 1999; Kendler et al. 2000; Gurling et al. 2001).
These earlier studies consisted mainly of analyses of
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Table 4
Distribution of Two-Marker Haplotypes
for D17S1529-D17S831 Chromosomes
Transmitted and Nontransmitted from Parents to
Probands
Haplotypea
Transmitted
(%)
Nontransmitted
(%)
2-1 2.84 .00
2-3 5.11 3.15
2-4 3.41 3.15
2-5 4.55 6.30
2-6 4.55 5.51
3-3 3.41 1.57
3-5 4.55 2.36
5-3 11.93 6.30
5-6 2.84 4.72
6-3 3.98 4.72
6-4 2.84 2.36
6-5 2.84 3.94
6-6 5.11 3.15
7-3 2.84 .00
8-2 5.68 2.36
Other (n p 48) 33.52 50.39
a Haplotype counts of at least 5 for either trans-
mitted or nontransmitted categories are reported
here; counts !5 are grouped in the category “other.”
Figure 2 Estimates of LD on chromosome 8p. A, Haplotype
results of AHR tests. The log10 (P value) from four different tests,
each using three markers, are plotted against genetic distance from
marker D8S1819. Estimates of a were between 0.06 and 0.16, and
estimates of g were between 10 and 20. B, Two-point results from the
LD-T tests. The –log10 (P value) is plotted from tests for which the
estimate of l was greater than the null hypothesis of zero. (Both
D8S1819 and D8S552 had l estimated to be zero.) Estimates of l
were 0.25–0.46
affected sib pairs or multiple small pedigrees, and, con-
sequently, the candidate region suggested by these stud-
ies is wide (covering as much as ∼50 cM); however, the
BP-I candidate segment suggested by our LD analyses
is close to the center of this region.
Other regions highlighted by the LD analysis show
less consistent evidence for BP-I localization than does
8p, but they still warrant follow-up investigations.
Marker D2S156 showed the strongest genomewide sta-
tistical evidence of LD of any marker, but the segment
surrounding this locus also displays substantial LD on
nontransmitted chromosomes (i.e., BLD), and there is
no striking visual evidence of overrepresentation of par-
ticular haplotypes on disease chromosomes (data not
shown). Similarly, on chromosome 17p, evidence for
association of BP-I extended over a 10-cM region, en-
compassing five markers, but visual inspection does not
point toward overrepresentation of particular haplo-
types in transmitted chromosomes, compared with non-
transmitted chromosomes (table 4). No markers in 17p,
however, are as closely spaced as markers on 8p, and
therefore we would not expect to detect as much hap-
lotype conservation. It is precisely in these situations
that a method like AHR may be able to detect LD that
is not readily identified by visual inspection.
As with most common disorders—even those in an
isolate—it is likely that several different susceptibility
alleles determine the genetic risk of BP-I at the popu-
lation level and that these alleles vary in their contri-
bution to the total risk. The parameter a provides a
rough assessment of the relative contributions that var-
ious genome segments make to risk, through estimation
of the proportion of disease chromosomes that share a
common ancestor. The demographic history of the study
population can dramatically affect such estimates. This
history explicitly connects two parameters estimated in
the reconstruction of ancestral haplotypes in a sample
of patients: the proportion of individuals who share an
ancestral chromosome (a), and the number of genera-
tions separating the patients from the introduction of
that chromosome into the population (g). A similar di-
versity of haplotypes, at the level of resolution of the
genome screen, could be observed in the sample under
widely varying values of a and g. If the ancestor was
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far in the past (large g), many different haplotypes
would be expected, which would be consistent with a
larger estimate for a. Alternatively, the ancestor could
have been recent, in which case one would expect more
haplotype conservation. To match the observed hap-
lotype diversity, then, a must be lower. The estimates
of a and g are not independent, and higher estimates
of g may be associated with higher a. In fact, very sim-
ilar expected distributions of haplotypes can be gener-
ated with a high g and high a and with a low g and
low a.
In our view, the results of genomewide screening for
LD for complex traits are best used to guide follow-up
studies of the highlighted chromosomal regions, and
they do not necessarily indicate statistically significant
associations. Several statistical issues remain unresolved
in the determination of appropriate significance levels
for such genomewide studies (Kruglyak 1997). It is not
clear what adjustment should be used to correct for the
multiple tests that are performed in genomewide LD
mapping. Resampling methods are not feasible because
of the very extensive computing time that they would
require, and a simple correction, such as the Bonferroni
procedure, is far too conservative when tests are not
independent. As our group and others have demon-
strated, recently founded isolates, such as the popu-
lation of the CVCR, display LD between a high pro-
portion of markers that are separated by several
centimorgans from each other. Clearly, in these popu-
lations, the LD tests used to map the disease phenotype
are far from independent. The level of dependence be-
tween such tests in a genomewide screen depends on
the degree of relatedness of the population studied, and
it is important to develop correction procedures that
will take into account the expected level of dependence
in a population. Furthermore, expectations for ge-
nomewide significance in traditional mapping studies
for simple Mendelian traits were based on the expec-
tation of finding a single major locus responsible for
the trait under study. A more stringent control for false
positives could be applied in such a situation. In the
case of a complex trait, however, one expects that there
will be multiple loci affecting the trait, and a very strict
control of the number of false positives, such as the
Bonferroni method, will result in a considerable loss of
power to identify secondary signals. Current research
in multiple-comparison procedures is focusing on cor-
rections that will handle dependent tests and multiple
true signals. For example, a promising measure of mul-
tiple-hypothesis–testing error called the “false discovery
rate” (Benjamini and Hochberg 1995) is currently being
investigated by members of our group for use in LD
mapping studies (C. Sabatti, S.K.S, and N.B.F., unpub-
lished data).
In our effort to further assess the observed signifi-
cance levels, we applied a goodness-of-fit test to the
results. Although this is a commonplace procedure in
statistical analysis in other disciplines, such goodness-
of-fit tests are rarely if ever applied in statistical genetics.
These tests provide an additional guide for interpreta-
tion of mapping studies for complex traits. Using the
results of these tests, the reader may judge not only the
level of significance of the mapping findings but also
whether the data are in reasonable agreement with the
assumptions of the method of analysis; in the present
study, these assumptions were rather restrictive (i.e.,
that disease chromosomes descend from a single ances-
tral haplotype).
An additional factor that complicates the interpre-
tation of LD mapping results, is that the tests used to
analyze LD usually treat affected individuals as inde-
pendent from one another, assuming equidistant con-
nections between them. As shown in figure 1, the sub-
jects in the present study are not equidistantly related.
The decision to treat individuals as independent serves
to artificially decrease the variance of the parameter
estimates, leading to an overstatement of the level of
significance of statistical tests. Other researchers have
attempted to address this issue by using a conditional
coalescent approach (McPeek and Strahs 1999) in LD
mapping; however, this correction applied uniformly to
genomewide results does not take into account the var-
iability across the genome in the degree of genetic sim-
ilarity between related subjects.
LD mapping of disease genes may be influenced by
the LD that exists throughout a population (i.e., by
BLD). Although BLD varies between genome regions
and between populations, we have shown that BLD is
extensive in the nontransmitted chromosomes of this
sample and that it extends, in many instances, across
several centimorgans (Service et al. 1999). We expect
BLD to be similarly extensive in other recently founded
isolated populations. Although we have reformulated
the AHR statistic to incorporate BLD between adjacent
markers in control chromosomes, more extensive BLD,
involving more than two loci, may still influence our
results. The data from chromosome 2 are an example of
the strong BLD that can exist on nontransmitted chro-
mosomes in our sample. It is unclear whether the signal
we are detecting around D2S156 is an artifact of BLD.
Alternatively, this signal may reflect BLD on top of a
disease-related association deriving from a haplotype
overrepresented on chromosomes in affected individuals.
The chromosomal regions in which we observed LD
for BP-I do not overlap with the regions suggested by
pedigree-based linkage studies of BP (Prathikanti and
McMahon 2001), including a study of our group that
was conducted in extended Costa Rican pedigrees
(McInnes et al. 1996). There are several possible ex-
planations for this observation. First, the present study
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is not directly comparable to previous mapping studies,
in that we employed a particularly narrow definition of
the BP phenotype, and all of the probands were severely
affected. Such a stringent definition of the affected phe-
notype is usually not feasible when patients are sampled
from pedigrees but is possible when the probands are
sampled from clinic populations. Second, none of the
localizations in the present or previous studies is suffi-
ciently unequivocal to rule out the possibility of false-
positive results. Third, even true susceptibility loci may
be specific to a particular study sample, especially if the
sample is drawn from a population isolate. Finally, the
expectations for pedigree- and population-based sam-
ples are different: in pedigrees, one may observe sus-
ceptibility alleles that are highly penetrant but are in-
frequent in the population; but, in population samples,
one expects lower-penetrance alleles that are relatively
prevalent. Alzheimer disease (AD) exemplifies these ex-
pectations; rare high-penetrance alleles have been ob-
served in a small number of extended pedigrees, and
the ApoE4 risk allele does not segregate in such pedi-
grees, although it is highly prevalent among patients
with AD in many different populations (Tanzi and Ber-
tram 2001).
Our results may also have been influenced by such
factors as substructure, admixture, or nonrandom mat-
ing that could have affected the pedigree and evolu-
tionary history of this patient sample. Although these
possibilities are not suggested by the extensive genea-
logical information that we have obtained or by the
empirical assessment of population homogeneity in our
sample, their presence could explain the variability be-
tween results of the present study and those of previous
association analyses of BP-I that we have conducted in
the CVCR. Although the sample used in the present
genome-screening study overlaps with the samples used
in our previous studies, for the present study we used
strict criteria for CVCR ancestry and included only the
probands for whom at least one parent was available
for genotyping (see “Subjects, Material, and Methods”
section). In our previous studies, the majority of subjects
did not fit these criteria. In addition, the markers used
in the present study were chosen from a single genetic
map and with the goal of providing equivalent coverage
of all chromosomes, whereas the markers used in the
previous studies, which were limited to chromosome 18,
were chosen from several genetic maps (Escamilla et al.
1999, 2001). The differences in markers and samples
could have been responsible for the fact that previous
LD analyses of the CVCR population samples (pro-
bands with BP-I and available relatives) identified as-
sociations on chromosome 18 (Escamilla et al. 1999,
2001) that were not observed in the analysis of the pres-
ent data set.
Clearly, genomewide LD mapping is in its early
stages, and general application for complex traits will
likely require both larger samples and denser marker
maps. The LD genome screen presented here has high-
lighted multiple regions that have overrepresented hap-
lotypes or alleles in 10%–40% of patients with BP-I.
Each of these regions could harbor a BP-I–susceptibility
gene, but no genome segment is associated with disease
in the majority of patients. Prioritizing these regions for
future work will require not only consideration of the
LD evidence from LD-T and AHR but also evaluation
of BLD in nontransmitted chromosomes and visual in-
spection of transmitted and nontransmitted haplotypes.
Regions selected for further analyses will be saturated
with additional markers in this patient sample and will
also be investigated in independently collected samples
of patients with BP-I from the CVCR and from other
populations. The results reported here should encourage
implementation of population-based mapping for other
complex traits in population isolates.
Acknowledgments
We thank Marjan Ophoff, for compiling the information in
figure 1; Joe DeYoung, for technical assistance; and Chiara
Sabatti, for helpful comments on the manuscript. R.A.O. was
partly supported by the TALENT stipend of the Netherlands
Organization for Scientific Research. This work was supported
by grants fromMillennium Pharmaceuticals, Inc., and the U.S.
National Institutes of Health.
References
Benjamini Y, Hochberg Y (1995) Controlling the false discov-
ery rate: a practical and powerful approach to multiple test-
ing. J R Stat Soc B 57:289–300
Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec
PS, Nestadt G, Thornquist M, et al (1998) Schizophrenia
susceptibility loci on chromosomes 13q32 and 8p21. Nat
Genet 20:70–73
Broman KW, Murray JC, Sheffield VC, White RL, Weber JL
(1998) Comprehensive human genetic maps: individual and
sex-specific variation in recombination. Am J Hum Genet
63:861–869
Brzustowicz LM, Honer WG, Chow EW, Little D, Hogan
J, Hodgkinson K, Bassett AS (1999) Linkage of familial
schizophrenia to chromosome 13q32. Am J Hum Genet
65:1096–1103
Chapman NH, Thompson EA (2001) Linkage disequilibrium
mapping: the role of population history, size, and structure.
Adv Genet 42:413–447
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A,
Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gya-
pay G, Morissette J, Weissenbach J (1996) A comprehensive
genetic map of the human genome based on 5,264 micro-
satellites. Nature 380:152–154
Escamilla MA, McInnes LA, Service SK, Spesny M, Reus VI,
Molina J, Gallegos A, Fournier E, Batki S, Neylan T, Mat-
thews C, Vinogradov S, Roche E, Tyler DJ, Shimayoshi N,
574 Am. J. Hum. Genet. 71:565–574, 2002
Mendez R, Ramirez R, Ramirez M, Araya C, Araya X, Leon
PE, Sandkuijl LA, Freimer NB (2001) Genome screening for
linkage disequilibrium in a Costa Rican sample of patients
with bipolar I disorder: a follow-up study on chromosome
18. Am J Med Genet 105:207–213
Escamilla MA, McInnes LA, Spesny M, Reus VI, Service SK,
Shimayoshi N, Tyler DJ, Silva S, Molina J, Gallegos A,Meza
L, Cruz ML, Batki S, Vinogradov S, Neylan T, Nguyen JB,
Fournier E, Araya C, Barondes SH, Leon P, Sandkuijl LA,
Freimer NB (1999) Assessing the feasibility of linkage dis-
equilibrium methods for mapping complex traits: an initial
screen for bipolar disorder loci on chromosome 18. Am J
Hum Genet 64:1670–1678
Escamilla MA, Spesny M, Reus VI, Gallegos A, Meza L, Mo-
lina J, Sandkuijl LA, Fournier E, Leon PE, Smith LB, Freimer
NB (1996) Use of linkage disequilibrium approaches to map
genes for bipolar disorder in the Costa Rican population.
Am J Med Genet 67:244–253
Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sher-
rington R, Mankoo BS, Read T, Murphy P, Blaveri E,
McQuillin A, Petursson H, Curtis D (2001) Genomewide
genetic linkage analysis confirms the presence of suscepti-
bility loci for schizophrenia, on chromosomes 1q32.2,
5q33.2, and 8p21-22 and provides support for linkage to
schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-
11.23. Am J Hum Genet 68:661–673
Houwen RH, Baharloo S, Blankenship K, Raeymaekers P, Juyn
J, Sandkuijl LA, Freimer NB (1994) Genome screening by
searching for shared segments: mapping a gene for benign
recurrent intrahepatic cholestasis. Nat Genet 8:380–386
Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D,
Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC,
Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne
D, Faraone SV, Tsuang MT, Cloninger CR (1998) NIMH
Genetics Initiative Millenium Schizophrenia Consortium:
linkage analysis of African-American pedigrees. Am J Med
Genet 81:282–289
Kendler KS, Myers JM, O’Neill FA, Martin R, Murphy B,
MacLean CJ, Walsh D, Straub RE (2000) Clinical features
of schizophrenia and linkage to chromosomes 5q, 6p, 8p,
and 10p in the Irish Study of High-Density Schizophrenia
Families. Am J Psychiatry 157:402–408
Kruglyak L (1997) What is significant in whole-genome link-
age disequilibrium studies? Am J Hum Genet 61:810–812
McInnes LA, Escamilla MA, Service SK, Reus VI, Leon P, Silva
S, Rojas E, Spesny M, Baharloo S, Blankenship K, Peterson
A, Tyler D, Shimayoshi N, Tobey C, Batki S, Vinogradov S,
Meza L, Gallegos A, Fournier E, Smith LB, Barondes SH,
Sandkuijl LA, Freimer NB (1996) A complete genome screen
for genes predisposing to severe bipolar disorder in two Costa
Rican pedigrees. Proc Natl Acad Sci USA 93:13060–13065
McPeek MS, Strahs A (1999) Assessment of linkage disequi-
librium by the decay of haplotype sharing, with application
to fine-scale genetic mapping. Am J HumGenet 65:858–875
Mohlke KL, Lange EM, Valle TT, Ghosh S, Magnuson VL,
Silander K, Watanabe RM, Chines PS, Bergman RN, Tuomi-
lehto J, Collins FS, Boehnke M (2001) Linkage disequilib-
rium between microsatellite markers extends beyond 1 cM
on chromosome 20 in Finns. Genome Res 11:1221–1226
Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C,
Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D,
Reich T (1994) Diagnostic interview for genetic studies: ra-
tionale, unique features, and training, NIMH Genetics Ini-
tiative. Arch Gen Psychiatry 51:849–859
Peltonen L, Palotie A, Lange K (2000) Use of population iso-
lates for mapping complex traits. Nat Rev Genet 1:182–190
Prathikanti S, McMahon FJ (2001) Genome scans for suscep-
tibility genes in bipolar affective disorder. AnnMed 33:257–
262
Pritchard JK, Stephen M, Donnelly P (2000) Inference of
population structure using multilocus genotype data. Ge-
netics 155:945–959
Risch NJ (2000) Searching for genetic determinants in the new
millennium. Nature 405:847–856
Schork NJ, Cardon LR, Xu X (1998) The future of genetic
epidemiology. Trends Genet 14:226–272
Risch N, Merikangas K (1996) The future of genetic studies
of complex human diseases. Science 273:1516–1517
Service SK, Ophoff RA, Freimer NB (2001) The genome-wide
distribution of background linkage disequilibrium in a pop-
ulation isolate. Hum Mol Genet 10:545–551
Service SK, Temple Lang DW, Freimer NB, Sandkuijl LA
(1999) Linkage-disequilibrium mapping of disease genes by
reconstruction of ancestral haplotypes in founder popula-
tions. Am J Hum Genet 64:1728–1738
Shifman S, Darvasi A (2001) The value of isolated populations.
Nat Genet 28:309–310
Tanzi RE, Bertram L (2001) New frontiers in Alzheimer’s dis-
ease genetics. Neuron 32:181–184
Terwilliger JD (1995) A powerful likelihood method for the
analysis of linkage disequilibrium between trait loci and
one or more polymorphic marker loci. Am J Hum Genet
56:777–787
Terwilliger JD, Shannon WD, Lathrop GM, Nolan JP, Goldin
LR, Chase GA, Weeks DE (1997) True and false positive
peaks in genomewide scans: applications of length-biased
sampling to linkage mapping. Am J HumGenet 61:430–438
Varilo T, Paunio T, Parker A, Meyer J, Terwilliger JD, Peltonen
L (2001) Significant linkage disequilibrium (LD) cover wide
intervals in alleles of the late settlement subpopulations of
Finland. Am J Hum Genet 69:197
